1 0
Cart
    Inquiry
    Popular Searches: Recombinant Antibody MHC Tetramer T cell Receptor Scaffold Protein
    + Filter
    Loading...
    Custom Services order now ship next day

    CD47

    Loading...

    Anti-CD47 Products

    More Infomation

    Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag

    More Infomation

    Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us

    For Research Use Only. Not For Clinical Use.


    Creative Biolabs is sincerely dedicated to accelerating the research and discovery process for the target CD47 by providing first-class, advanced recombinant antibodies specifically designed to target CD47. Our commitment to excellence is reflected in the meticulous development of each antibody, ensuring optimal specificity and performance for various applications. By equipping researchers with these high-quality tools, we aim to facilitate significant advancements in understanding CD47's role in immunology and cancer research, ultimately supporting groundbreaking discoveries that can lead to innovative therapeutic strategies.

    CD47: A Significant Surface Protein in Cancer

    CD47 is a cell surface protein that plays a crucial role in regulating immune responses. It is often referred to as a "don't eat me" signal, as it inhibits phagocytosis by macrophages. Research on CD47 is of significant importance as it holds potential in the treatment of various diseases, especially cancers. By targeting CD47, it is possible to enhance the immune system's ability to recognize and eliminate cancer cells. This could lead to the development of novel and more effective cancer therapeutics. Additionally, understanding the function of CD47 in immune regulation may provide insights into treating other immune-related disorders.

    Alternative Names

    CD47 molecule; IAP; OA3; MER6

    Background

    CD47 (CD47 Molecule) is a Protein Coding gene. Diseases associated with CD47 include Hereditary Spherocytosis and Neonatal Meningitis. Among its related pathways is the response to elevated platelet cytosolic Ca2+ and the Innate Immune System. Gene Ontology (GO) annotations related to this gene include thrombospondin receptor activity.

    Anti-CD47 rAb Products

    Our company is determined to hasten research and discovery by offering high-quality anti-CD47 recombinant antibody products at an extraordinary value together with superior technical support.

    Cat. No. Product Name Target Species Host Species Applications
    TAB-303LC Human Anti-CD47 Recombinant Antibody Human Human ELISA
    HPAB-0008-FY Human Anti-CD47 Recombinant Antibody Human Human ELISA; PD; Activ; PK; Stim
    HPAB-1278WJ Mouse Anti-CD47 Recombinant Antibody (clone MABL-1) Human Mouse ELISA; Cyt; PP; Inhib
    HPAB-0096-CN Human Anti-CD47 Recombinant Antibody Human Human ELISA; FC; Neut
    HPAB-N0334-YC Human Anti-CD47 Recombinant Antibody Human Human ELISA; Block

    Creative Quality Control

    Creative Biolabs has set up a rigorous quality management system to ensure the quality of our antibody products. Simultaneously, it helps our clients save time during the drug development process and fulfills their research and development requirements.

    Fig.1 SDS-PAGE analysis of TAB-303LC. (Creative Biolabs Original)Fig.1 SDS-PAGE analysis of anti-CD47 antibody
    (Cat# TAB-303LC, Creative Biolabs).

    Fig.2 SEC-HPLC analysis of HPAB-0008-FY. (Creative Biolabs Original)Fig.2 SEC-HPLC analysis of anti-CD47 antibody
    (Cat# HPAB-0008-FY, Creative Biolabs).

    Fig.3 ELISA analysis of HPAB-1278WJ. (Creative Biolabs Original)Fig.3 ELISA analysis of anti-CD47 antibody
    (Cat# HPAB-1278WJ, Creative Biolabs).

    Fig.4 WB analysis of HPAB-1278WJ. (Creative Biolabs Original)Fig.4 WB analysis of anti-CD47 antibody
    (Cat# HPAB-1278WJ, Creative Biolabs).

    Fig.5 DB analysis of HPAB-1278WJ. (Creative Biolabs Original)Fig.5 DB analysis of anti-CD47 antibody
    (Cat# HPAB-1278WJ, Creative Biolabs).

    Customer Reviews

    Excellent
    C**re
    Human Anti-CD47 Recombinant Antibody (Cat#: TAB-303LC)
    In my study related to immune disorders, I made use of the Human Anti-CD47 Recombinant Antibody. When using ELISA for assessment, the outcome was highly encouraging. The antibody effectively identified CD47, offering clear and consistent results. It proved to be an invaluable tool, facilitating my research and providing crucial insights into the mechanisms underlying immune dysregulation involving CD47.
    25/Aug/2022
    Excellent
    H**in
    Human Anti-CD47 Recombinant Antibody (Cat#: HPAB-0096-CN)
    I used the human anti-CD47 recombinant antibody in my study on cancer immunotherapy. I employed flow cytometry and neutralization assays for evaluation. The results were quite remarkable. With FC, it precisely identified the binding of the antibody to CD47 on tumor cells. The neutralization assays demonstrated its effective blocking of the CD47 signaling pathway, suggesting potential therapeutic efficacy.
    17/Feb/2023
    Excellent
    W**er
    Mouse Anti-CD47 Recombinant Antibody (clone MABL-1) (Cat#: HPAB-1278WJ)
    I employed the mouse anti-CD47 recombinant antibody in my study on tumor microenvironment. I conducted detection through ELISA and Inhibition assays. ELISA offered clear measurements of CD47 expression, while the Inhibition assays showcased its potential in modulating related pathways. The antibody was essential for my study, enabling me to make significant progress and obtain conclusive results.
    8/Apr/2023

    Anti-CD47 rAb Production

    Our company's platform has many years of experience in aspects such as vector construction and antibody production. Therefore, we have the ability to provide high-quality antibody production services for research professionals.

    Featured Anti-CD47 Recombinant Antibody Production PlatformsFig.6 Milligram-scale anti-CD47 recombinant antibody production. (Creative Biolabs Original)
    Fig.6 Milligram-scale recombinant antibody production.

    Fig.7 Gram-scale anti-CD47 recombinant antibody production. (Creative Biolabs Original)Fig.7 Gram-scale recombinant antibody production

    rAb Modalities

    After years of exploration, Creative Biolabs can provide researchers with the most comprehensive and advanced high-quality recombinant antibodies of various types to meet the diverse research and development needs of customers.

    Fig.8 Full Length Anti-CD47 Recombinant Antibody Production and Modalities. (Creative Biolabs Original)Fig.8 Full Length Anti-CD47 Recombinant Antibody Production and Modalities

    Drug Information Targeting CD47

    Table 1. Therapeutic approaches targeting CD47 in clinical development.

    Research phase Company Classification Indications Details
    Phase III AbbVie Human Monoclonal Antibody Acute myeloid leukemia;
    Cancer     		This is a fully human monoclonal antibody targeted at CD47 being developed by I-Mab Biopharma as a treatment for several cancers and hematological malignancies.
    Phase II/III Alexo Therapeutics Fc Fusion Proteins Acute myeloid leukemia;
    Cancer     		It is an Fc fusion protein targeted at CD47 in phase II/III clinical development at AXL Oncology (formerly Alexo Therapeutics) for the treatment of HER2-overexpressing advanced/metastatic gastric and gastroesophageal junction adenocarcinomas progressing after prior therapy.
    Phase II Waterstone Pharmaceuticals Bispecific Antibody Cancer This is a bispecific antibody targeting CD47 and PD-1, is in early clinical development at Waterstone Pharmaceuticals for the treatment of advanced solid tumors.
    Phase II Akeso Biopharma Humanized Monoclonal Antibody Acute myeloid leukemia This is a humanized monoclonal antibody targeting CD47 in phase II clinical development at Akeso as treatment for locally advanced or metastatic triple-negative breast cancer (TNBC).
    Phase II Pfizer Fc Fusion Proteins Acute myeloid leukemia;
    Cancer     		It is an anti-CD47 Fc fusion protein, comprising the CD47-binding domain of SIRPalpha and an IgG4 Fc moiety.
    Phase II Pfizer Fc Fusion Proteins Acute lymphocytic leukemia This is a CD47-blocking Fc fusion protein comprising the CD47-binding domain of SIRPalpha and an IgG1 Fc moiety.
    Phase II Gilead Humanized Monoclonal Antibody Acute myeloid leukemia;
    Cancer     		It is a humanized monoclonal antibody targeting CD47 developed by Gilead.
    Phase I/II Centessa Pharmaceuticals Bispecific Antibody Fusions Cancer It is a bispecific PD-L1xCD47 LockBody(R), is in early clinical development at Centessa Pharmaceuticals for the treatment of advanced solid tumors.
    Phase I/II Mabwell (Shanghai) Bioscience Bispecific Antibody Acute myeloid leukemia;
    Cancer     		This is an anti-CD47/PD-L1 bispecific antibody in early clinical development at Mabwell (Shanghai) Bioscience as monotherapy for the treatment of patients with advanced malignant neoplasms.
    Phase I/II Ichnos Sciences Bispecific Antibody Multiple myeloma This is a barotropic 2+1 bispecific antibody comprising two arms targeting different epitopes of CD38 and another arm targeting CD47.
    Phase I/II ImmuneOnco Fc Fusion Proteins Acute myeloid leukemia;
    Cancer     		It is a CD47-targeted fusion protein comprising an anti-CD47 antibody fused to human SIRP-alpha being developed by ImmuneOnco.
    Phase I/II China Shijiazhuang Pharmaceutical Fusion Proteins Lymphoma; Non-Hodgkin lymphoma This is a CD20-CD47 bispecific fusion protein in early clinical development at China Shijiazhuang Pharmaceutical (CSPC) in the US for the treatment of patients with advanced CD20-associated non-Hodgkin's lymphomas.
    Phase I/II Phanes Therapeutics Bispecific Antibodies Cancer It is an anti-Claudin 18.2/anti-CD47 bispecific antibody, that is in early clinical development at Phanes Therapeutics for the treatment of patients with advanced gastric, gastroesophageal junction and pancreatic adenocarcinomas.
    Phase I/II ImmuneOnco Fusion Proteins Cancer This is a cancer immunotherapy consisting of a recombinant bifunctional protein targeting CD47 and HER2.

    For additional information on our anti-CD47 recombinant antibody products, please do not hesitate to reach out to us. Our team is eager to provide assistance and answer any questions you may have. We look forward to fostering a friendly and productive collaboration that supports your research endeavors.

    Go to compare

    Go to compare